ABSTRACT BACKGROUND Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF).
A n important cause of mortality and morbidity in children, pediatric heart failure (HF) contributes substantially to health care costs (1) . Pediatric cardiomyopathies are a prominent cause of HF in children, with an annual incidence of 11 to 12 children per million/year in the United States and Australia (2, 3) . Dilated cardiomyopathy (DCM) represents one-half of all cardiomyopathies in children.
Although the overall incidence of pediatric DCM is low, it is higher in children age <1 year (44 cases per million/year) than in children older than age 3 years (3.4 cases per million/year) (4) . Although some children recover normal left ventricular (LV) function and size (5) , DCM is often associated with poor outcomes. Approximately 40% of children undergo cardiac transplantation or die within 5 years of DCM diagnosis, attesting to the importance of HF in this patient population (6, 7) .
Management of children with chronic HF can be challenging. Proposed treatment guidelines for HF in childhood have been hampered by a paucity of evidence-based pediatric data (8, 9) . Available therapies include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretic agents, and digoxin (10, 11) . However, with a lack of clinical trials, these treatments are not approved for use in children.
Nonetheless, these agents have been shown to be beneficial in small studies as well as in current practice, and as such, they are proposed in the guidelines for the management of chronic HF in children (8, 9) .
To date, no randomized controlled trial of any medication has demonstrated a significant improvement of HF outcomes in pediatric patients. A study in 161 children ages 0 to 17 years with chronic HF (12) indicated that the beta-blocker carvedilol had no significant effect on chronic HF outcomes in children compared with placebo, although there was some improvement in left ventricular ejection fraction (LVEF).
In adults, an elevated heart rate is associated with an increased risk of death in patients with chronic HF (13) (14) (15) . Ivabradine, an effective heart rate-reducing agent, lowers incidence of cardiovascular death and hospitalization for worsening HF in adult patients, with a relative risk reduction of 18% in a trial setting (p < 0.0001) (16) . Ivabradine is recommended for the treatment of chronic HF in adults with an elevated heart rate and in sinus rhythm (17) . There are no corresponding data for ivabradine in children. The objective of our study was to document the effect of ivabradine therapy in a pediatric population age 6 months to 18 years with DCM and symptomatic chronic HF. We explored the dose of ivabradine that was necessary to reach a $20% reduction in heart rate, and we evaluated its tolerance. We also describe its effect on (documented by echocardiography) on stable treatment for chronic HF were considered eligible. Patients enrolled were stratified into 3 subgroups (age 6 to 12 months, >1 year and < 3 years, and 3 to 18 years), and were then randomly allocated to treatment with either ivabradine or placebo in a 2:1 ratio. Treatment was allocated via a centralized interactive randomization response system. The primary objectives of the study were to: 1) determine the optimal dose of ivabradine to reach a target heart rate reduction of $20% without bradycardia; and 2) assess the pharmacokinetic profile and pharmacokineticpharmacodynamic relationship of ivabradine in children. This report describes the results pertaining to the target heart rate reduction. Pharmacokinetic results have been reported in separate publications (19, 20) .
Study inclusion required HF functional class to be stable for at least 4 weeks prior to selection. Eligible patients were in sinus rhythm with resting heart rates in the normal range for age: $105 beats/min for patients ages 6 to 12 months, $95 beats/min for >1 year and <3 years, $75 beats/min for 3 to 5 years, and $70 beats/min for 5 to 18 years; these values were predefined according to normal limits reported in healthy pediatric patients (21) . Lower-limit values were pre-specified, because most patients were already receiving beta-blockers. The minimal resting heart rate at inclusion for 5-to 18-year-olds was fixed at $70 beats/min based on studies in adults (16) . Neonates and infants (age <6 months) were excluded due to concerns over tolerability of the use of 2 heart ratelowering agents (beta-blockers and ivabradine) (22, 23) . Bonnet et al.
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Ivabradine in Pediatric Heart Failure patients gave their written informed consent, and depending upon age and local regulations, children and adolescents also gave their informed assent. The International Scientific Board had the overall scientific responsibility of the study, and the Data and Safety Monitoring Board operated independently of the study's sponsor and reviewed safety data. The trial is registered on the European Clinical Trials Register (ISRCTN60567801).
PROCEDURES AND ENDPOINTS.
There was a 2-to 8-week titration period with periodic visits. Previous results in adults showed that the greatest heart rate reduction with ivabradine (19% to 25%) was obtained in patients with the highest heart rate at baseline, which correlated with the greatest improvement in outcome events versus placebo (24) . A mean heart rate reduction of 20% was observed to be clinically beneficial for adult patients in the SHIFT (Ivabradine and Outcomes in Chronic Heart Failure) study (16) . Consequently, the dosage of study treatment was uptitrated to achieve a $20% reduction in heart rate without inducing bradycardia or its symptoms. Bradycardia was defined as a heart rate of <80 beats/min for patients ages 6 to 12 months, <70 beats/min for >1 year and <3 years, and <50 beats/min for 3 to 18 years. If the patient experienced bradycardia, the study drug was downtitrated to the next lowest dosage.
Study treatment was administered as an oral liquid at a starting dose of 0.02 mg/kg twice daily for children ages 6 to 12 months and 0.05 mg/kg twice daily for children ages >1 year and < 3 years or 3 to 18 years. This liquid ivabradine was specially formulated for this pediatric study, and was delivered as single-dose units of 10 ml containing 1, 5, or 13.3 mg of ivabradine (stored at room temperature). The tablet form (adult formulation) was administered to children weighing $40 kg with a starting dose of 2.5 mg twice daily. The doses could be adjusted every 2 weeks (increased, decreased, or maintained). The duration of the titration period was governed by the magnitude of heart rate reduction and could last up to 8 weeks or until the patient reached the primary endpoint ($20% reduction in heart rate without bradycardia or symptoms of bradycardia). The titration period was followed by a 2-week maintenance period. This was followed by monitoring for a further 12 months on treatment, with monthly visits up to 3 months, and then visits at 6, 9, and 12 months.
At every visit, patient heart rate was measured using any method, provided that the child was quiet and at rest, and the dose of study treatment was recorded. Children ages 5 to 18 years personally responded to age-adapted questionnaires, as did their parents. The improvement in total score (0 to 100 scale) was expressed as a change from baseline of >4.5.
The safety of ivabradine was monitored throughout the study. Moreover, patients were hospitalized overnight for medical observation after the first treatment administration, and observed for at least 4 h after the second intake. All treatmentemergent adverse events (AEs) were classified using the Medical Dictionary for Regulatory Activities (26).
STATISTICAL METHODS. The sample size was determined based on the pharmacokinetic objective, which was 1 of the study's primary objectives. Considering the unbalanced design between ivabradine and placebo (2:1), it was estimated that at least 90 evaluable children were to be included in this study (60 ivabradine, 30 placebo) to explore the pharmacokineticpharmacodynamic relationship of ivabradine. This number of patients allowed the detection of a difference of at least 10% in LVEF units between ivabradine and placebo, assuming an SD of 12%, with a 95% power and a type I error of 5% (2-sided), based on a Student t test.
The baseline characteristics are presented as means AE SD for continuous variables and as numbers and percentages for categorical variables. At the end of the titration period, the number and percentage of patients who reached the primary endpoint (achievement of target heart rate reduction) are presented for patients in the full-analysis set (FAS) population (i.e., all patients having received at least 1 dose of treatment and at least 2 evaluations of heart rate: at baseline and at least 1 time during follow-up). These data were also recorded for patients in the per-protocol population (i.e., all patients having completed the titration period in accordance with the protocol).
For the primary endpoint, treatment effect was estimated using a logistic regression model adjusted for age group in the overall population, and unadjusted in each age class. An estimate of the odds ratio (OR) between treatment groups and corresponding 95% confidence interval (CI) and p value are provided.
Changes from baseline to the end of titration period and 12 months (for heart rate), and to 6 and 12 months Table 1) .
The NT-proBNP plasma concentration was 1,682 AE 3,224 pg/ml (geometric mean: 484 pg/ml). Overall, baseline characteristics were well-balanced between treatment groups.
HEART RATE REDUCTION AND DOSE. For all age groups combined, the primary endpoint ($20% reduction of the baseline resting heart rate without bradycardia or symptoms of bradycardia) was reached by more children receiving ivabradine (70%) than placebo (12%) in the FAS population. The betweengroup comparison was statistically significant in (18) Values are mean AE SD (median) or n/N (%). *The mean dose was defined as the sum of doses prescribed, taking into account the number of days for which a dose was prescribed during the titration period. Dosing was twice daily.
favor of ivabradine (OR: 17.24; 95% CI: 5.91 to 50.30; p < 0.0001) ( Table 2) . Similar results were observed in the per-protocol population: among the 18 patients on ivabradine who did not reach the primary endpoint, 15 patients had a heart rate reduction of <20% at the highest dose, and 3 patients experienced asymptomatic bradycardia. Regardless of age, the effect of ivabradine upon resting heart rate was A similar and substantial decrease in NT-proBNP was observed in both the ivabradine and placebo groups between baseline and 12 months. The decreases were À710 AE 1,478 pg/ml (median À128 pg/ml) with ivabradine and À367 AE 576 pg/ml (median À129 pg/ml) with placebo. Table 2) ; similar results were observed at 12 months.
SAFETY. The overall safety of ivabradine was comparable to the placebo group. Adverse events were reported at a similar frequency in both treatment groups (86% with ivabradine vs. 88% with placebo) ( Table 4 ). The most frequently affected system organ classes were infections and infestations (mainly nasopharyngitis, bronchitis, upper respiratory tract infection, and viral infection), and gastrointestinal disorders (mainly gastroenteritis, diarrhea, and vomiting), with a lower frequency of AEs with ivabradine than placebo. A prolonged QTc interval was observed less frequently with ivabradine than placebo (8% vs. 17%), and led to study withdrawal in 4%
and 7% of patients, respectively. None of the emergent QTc prolongations in the ivabradine group were serious or symptomatic. Phosphenes were reported at a similar frequency in both groups. None of the patients reported blurred vision. Globally, cardiac concerns were reported less frequently by patients on ivabradine than placebo (15% vs. 31%, respectively), and led to withdrawal in the placebo group only.
Bradycardia-asymptomatic cases included-was reported with a higher frequency with ivabradine than placebo (11.0% vs. 2.4%). Symptomatic bradycardia was reported in the ivabradine group only: 4% in the age >1 year and <3 years subgroup and 5% in the age 3 to 18 years subgroup. Emergent bradycardia led to a dose reduction in 6 patients (1.6%), all with ivabradine, none of which led to study withdrawal. No patient died in the ivabradine group, but 4 patients (9.5%) died in the placebo group (between-group difference: p ¼ 0.016) ( Table 4) . A total of 3 heart transplants were performed (2.5%): 1 in the ivabradine group and 2 in the placebo group. Additionally, 1 patient on ivabradine underwent a heart transplant 2 months after the last study drug intake.
DISCUSSION
In children with DCM and symptomatic chronic HF, adding ivabradine to stable HF therapy (including beta-blockers) could reduce heart rate by more than 20% in a clear majority of children without inducing bradycardia. Ivabradine showed similar efficacy for reducing heart rate in a wide range of age classes, from 6 months to 18 years (Central Illustration). We observed a high interindividual variability in response to ivabradine, indicating that dose titration is important-and should be mandatory-when used to treat children with chronic HF. Ivabradine treatment was associated with significant improvement in LVEF (þ14%) and LVESV (À16.2 AE 27.0 ml) at 12 months, greater than that seen with placebo (þ7% and À1.9 ml for LVEF and LVESV, respectively). In line with this This randomized, double-blind, placebo-controlled trial explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure (HF). The primary endpoint (reduction of $20% of heart rate from baseline without bradycardia) was reached in a significantly higher proportion in the treatment arm. As to secondary endpoints, significant improvement of left ventricular ejection fraction (LVEF) was significantly better in the treatment arm; the other secondary endpoints were not significantly different but trended towards improvement with ivabradine.
heart rate at follow-up when treating chronic HF in children with DCM who are taking ivabradine. The rates of known AEs with ivabradine, such as phosphenes and bradycardia, were in line with the rates observed in adults (16) . QTc prolongations were less frequent with ivabradine than placebo. The results of the pharmacokinetic and pharmacodynamic analysis showed that the relationship described in adults was conserved in the pediatric population (19, 20) .
The majority of patients in this study were treated with combinations of recommended drugs (ACE in- 
